Report #2847119

Overview

Sex

Female

Age

37 yrs

State

NY

Recovered

Unknown

Vaccinated

Jul 20, 2015

Onset

Jul 20, 2015

Days to onset

0

Hospital days

—

Symptoms (1)

Symptom narrative

Engerix-B late third dose; Engerix-B late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 37-year-old female patient who received HBV (Engerix B) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (received 1st dose on 03-NOV-2014). On an unknown date, the patient received the 3rd dose of Engerix B. On 20-JUL-2015, the patient received the 2nd dose of Engerix B. On 20-JUL-2015, not applicable after receiving Engerix B and an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Engerix-B late second dose). On an unknown date, the patient experienced drug dose administration interval too long (Verbatim: Engerix-B late third dose). The outcome of the drug dose administration interval too long and drug dose administration interval too long were not applicable. Additional Information: GSK Receipt Date: 13-JUN-2025 The pharmacist reported that an adult female patient had received a first Engerix-B dose on 03rd November 2014 and a second Engerix-B on 20th July 2015 and received 3rd dose late. No data about lot number or expiration dates. The vaccine administration facility was the same as primary reporter. The patient received 2nd and 3rd dose later than official recommendation which led to lengthening of vaccination schedule.